A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 15, 2016

Study Completion Date

July 31, 2016

Conditions

Cytomegalovirus DiseaseKidney Transplant Infection

Interventions

DRUG

Brincidofovir

DRUG

Valganciclovir

Trial Locations (3)

University of Colorado Hospital/Health Science Center, Aurora

St. Vincent Medical Center, Los Angeles

Yale New Haven Hospital, New Haven